MetaCap

Palatin Technologies (PTN) vs Quantum Biopharma (QNTM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Quantum Biopharma (QNTM) has outperformed Palatin Technologies (PTN) over the past year, losing 77.6% versus a loss of 79.9%. Over five years, QNTM leads with a -98.5% price change compared with -99.3% for PTN. Quantum Biopharma is the larger company by market cap ($8.3 million vs $8.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PTN-79.93%QNTM-77.60%
+107%+9%-89%
Nov 21, 20251 yearNov 20, 2026
PTN-98.98%QNTM-98.66%
+69%-19%-107%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PTN versus QNTM key metrics
MetricPTNQNTM
Share price$4.58$1.29
Market cap$8.16M$8.29M
1-day change-7.10%-9.15%
YTD return-70.22%-82.33%
1-year return-79.93%-77.60%
5-year return-99.35%-98.51%
EPS (TTM)$-2.96$-3.42
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$8.83M—
Net income (latest FY)$-8.38M—
Operating margin-98.17%—
Net margin-94.88%—
52-week high$31.00$12.42
52-week low$4.51$1.26
Distance from 52-week high-85.23%-89.61%
Analyst consensusstrong_buynone
Avg. price target upside+1068.12%+851.16%
Average volume71.93K148.83K
Shares outstanding1.78M6.43M
Employees25—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Palatin Technologies

PTN stock →

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity completed Phase 2 clinical trial; completed a phase 2 of diabetic nephropathy It also provides pl9643 for dry eye disease; and oral PL8177 for inflammatory bowel diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees

About Quantum Biopharma

QNTM stock →

Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments.

Health Care · Biotechnology: Pharmaceutical Preparations

PTN vs QNTM FAQ

Which is bigger, Palatin Technologies or Quantum Biopharma?

Quantum Biopharma (QNTM) is larger, with a market capitalization of $8.29M compared with $8.16M for Palatin Technologies (PTN).

Which stock has performed better over the past year, PTN or QNTM?

QNTM returned -77.60% over the past 12 months, compared with -79.93% for PTN (price return, excluding dividends). Past performance does not predict future results.

Are Palatin Technologies and Quantum Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons